Literature DB >> 15498586

An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.

Muneya Fujimoto1, Hiroaki Masuzaki, Tomohiro Tanaka, Shintaro Yasue, Tsutomu Tomita, Kayoko Okazawa, Junji Fujikura, Hideki Chusho, Ken Ebihara, Tatsuya Hayashi, Kiminori Hosoda, Kazuwa Nakao.   

Abstract

Evidence has accumulated that some of the angiotensin II AT1 receptor antagonists have insulin-sensitizing property. We thus examined the effect of telmisartan on insulin action using 3T3-L1 adipocytes. With standard differentiation inducers, a higher dose of telmisartan effectively facilitated differentiation of 3T3-L1 preadipocytes. Treatment of both differentiating adipocytes and fully differentiated adipocytes with telmisartan caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and adiponectin. By contrast, telmisartan attenuated 11beta-hydroxysteroid dehydrogenase type 1 mRNA level in differentiated adipocytes. Of note, we demonstrated for the first time that telmisartan augmented GLUT4 protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15498586     DOI: 10.1016/j.febslet.2004.09.027

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  18 in total

Review 1.  Telmisartan: a review of its use in the management of hypertension.

Authors:  Anna J Battershill; Lesley J Scott
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  The renin-angiotensin-aldosterone system and glucose homeostasis.

Authors:  James Matthew Luther; Nancy J Brown
Journal:  Trends Pharmacol Sci       Date:  2011-08-29       Impact factor: 14.819

3.  Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice.

Authors:  X Rong; Y Li; K Ebihara; M Zhao; J Naowaboot; T Kusakabe; K Kuwahara; M Murray; K Nakao
Journal:  Diabetologia       Date:  2010-08       Impact factor: 10.122

4.  Uric acid induces oxidative stress via an activation of the renin-angiotensin system in 3T3-L1 adipocytes.

Authors:  Jun-xia Zhang; Yu-ping Zhang; Qi-nan Wu; Bing Chen
Journal:  Endocrine       Date:  2014-03-28       Impact factor: 3.633

5.  Losartan Inhibits Vascular Smooth Muscle Cell Proliferation through Activation of AMP-Activated Protein Kinase.

Authors:  Jung Eun Kim; Hyoung Chul Choi
Journal:  Korean J Physiol Pharmacol       Date:  2010-10-31       Impact factor: 2.016

6.  The effects of the renin-angiotensin-aldosterone system gene polymorphisms on insulin resistance in hypertensive families.

Authors:  Chin-Fu Hsiao; Wayne W H Sheu; Yi-Jen Hung; Ming-Wei Lin; David Curb; Koustubh Ranadex; Thomas Quertermous; Yue-Ming Chen; Ida Yi-Der Chen; Kwan-Dun Wu
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2012-03-14       Impact factor: 1.636

Review 7.  New standards in hypertension and cardiovascular risk management: focus on telmisartan.

Authors:  Domenico Galzerano; Cristina Capogrosso; Sara Di Michele; Antonio Galzerano; Paola Paparello; Diana Lama; Carlo Gaudio
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

8.  Control of adipogenesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways.

Authors:  Aung Than; Melvin Khee-Shing Leow; Peng Chen
Journal:  J Biol Chem       Date:  2013-04-16       Impact factor: 5.157

9.  BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.

Authors:  Joachim Schrader; Peter Bramlage; Stephan Lüders; Martin Thoenes; Andreas Schirmer; Dieter W Paar
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

10.  [Antihypertensive and metabolic effects of telmisartan in patients with the metabolic syndrome in primary care--a field study].

Authors:  Barbara Tripp; Bernhard Ludvik
Journal:  Wien Med Wochenschr       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.